Skip to Main Content

Approximately 80% of salivary gland tumors occur in the parotid gland. In adults, about 80% of these are benign. In the submandibular triangle, it is sometimes difficult to distinguish a primary submandibular gland tumor from a metastatic submandibular space node. Only 50–60% of primary submandibular tumors are benign. Tumors of the minor salivary glands are most likely to be malignant, with adenoid cystic carcinoma predominating, and may be found throughout the oral cavity or oropharynx.

Most parotid tumors present as an asymptomatic mass in the superficial part of the gland. Their presence may have been noted by the patient for months or years. Facial nerve involvement correlates strongly with malignancy. Tumors may extend deep to the plane of the facial nerve or may originate in the parapharyngeal space. In such cases, medial deviation of the soft palate is visible on intraoral examination. MRI and CT scans have largely replaced sialography in defining the extent of tumor. At least one new study demonstrates the potential benefit of enhanced MRI imaging in distinguishing among Warthin tumors and pleomorphic adenomas and malignant salivary gland tumors.

When the clinician encounters a patient with an otherwise asymptomatic salivary gland mass where tumor is the most likely diagnosis, the choice is whether to simply excise the mass via a parotidectomy with facial nerve dissection or submandibular gland excision or to first obtain an FNA biopsy. Although the accuracy of FNA biopsy for malignancy has been reported to be quite high, results vary among institutions. If a negative FNA biopsy would lead to a decision not to proceed to surgery, then it should be considered. Poor overall health of the patient and the possibility of inflammatory disease as the cause of the mass are situations where FNA biopsy might be helpful. In otherwise straightforward nonrecurrent cases, excision is indicated. In benign and small, low-grade malignant tumors, no additional treatment is needed. Postoperative irradiation is indicated for larger and high-grade cancers.

+
D’heygere  E  et al. Salivary duct carcinoma. Curr Opin Otolaryngol Head Neck Surg. 2018 Apr;26(2):142–51.
[PubMed: 29373327]
+
Ogawa  T  et al. Clinical utility of dynamic-enhanced MRI in salivary gland tumors: retrospective study and literature review. Eur Arch Otorhinolaryngol. 2018 Jun;275(6):1613–21.
[PubMed: 29623392]
+
Sood  S  et al. Management of salivary gland tumours: United Kingdom national multidisciplinary guidelines. J Laryngol Otol. 2016 May;130(S2):S142–9.
[PubMed: 27841127]

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.